Medical Distribution: McKesson Corporation owns the largest revenue base; Cardinal Health, Inc. has the fastest current growth.
The industry itself · before any single company
How has Medical Distribution moved against S&P 500?
The line below covers 5.2 years. Over the most recent two of them this industry is 25% ahead of S&P 500. Earnings across its companies grew 23% on average over the last four reported quarters.
TURNING · ahead 3w~Price and the fundamentals both up3 of 7 companies ahead of S&P 500 by 5% or more over three months
Medical Distribution, equal-weighted, based at 200S&P 500, same base, same starttrailing 12-month earnings per share risingfalling
Strength anatomyMixedHow much of the industry is participating, how recently, and whether the movers score well.
Together3 of 7 stocks moving
Fresh2 crossed in the last 4 weeks
Backed by scoresmovers score −2 vs the industry average
Down the cap ladder — bar is now, tick is four weeks ago
Large0/20
Mid2/2+2
Small1/3−1
Participation is spreading downward — the mid and small companies added more this month than the large ones did.
Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 7 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Medical Distribution outperforming S&P 500?
Medical Distribution has outperformed S&P 500 by 40.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 6.4%. 4 of 7 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. EDAP TMS S.A. is the strongest against the sector itself at +46.7%.
+6.4%Sector vs S&P 500 · 13 weeks
+40.3%Sector vs S&P 500 · 52 weeks
4/7Stocks leading S&P 500
1/7Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Medical Distribution has outperformed S&P 500 by 40.3% over 52 weeks and 6.4% over 13 weeks. 4 of 7 covered companies beat the S&P 500 on Mansfield relative strength, while 1 of 7 beat the sector itself. McKesson Corporation leads with revenue of $403,430 million, based on 6 of 8 comparable companies through Mar 2026.
Is the Medical Distribution sector outperforming S&P 500?
Medical Distribution has outperformed S&P 500 by 40.3% over 52 weeks and 6.4% over 13 weeks. 4 of 7 covered companies beat the S&P 500 on Mansfield relative strength, while 1 of 7 beat the sector itself.
Which Medical Distribution company is largest by revenue?
McKesson Corporation leads with revenue of $403,430 million, based on 6 of 8 comparable companies through Mar 2026.
Which Medical Distribution company is growing fastest?
Cardinal Health, Inc. has the fastest current revenue growth at 12.8%, across 6 of 8 comparable companies.
Which Medical Distribution company has the strongest 4-Factor Sector Score?
McKesson Corporation ranks first at 71.7/100 with 80.5% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Medical Distribution company reports the most CAPEX?
Cencora, Inc. reports the largest latest CAPEX at $166 million, with 8 of 8 companies comparable.
Which Medical Distribution company has the least gross debt?
Empro Group Inc. has the lowest comparable gross debt at $2 million. Cencora, Inc. has the highest at $12,386 million.
Which Medical Distribution company has the lowest comparable PEG?
McKesson Corporation has the lowest comparable Guarded PEG at 0.46, among 4 of 8 companies that pass the metric’s comparability rules.
How much history does this Medical Distribution comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
8
complete canonical membership
Combined market value
$232.4B
McKesson Corporation
Revenue growing
5/6
positive TTM year-on-year growth
Beating S&P 500
4/7
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
McKesson Corporation has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 80.5% evidence confidence.
Cardinal Health, Inc. looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Cardinal Health, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17.5/35Growth & earnings
Revenue — · PAT — · OPM change —
12% evidence
7.8/25Capital efficiency
ROCE -0.7% · debt/equity —
46% evidence
10.0/20Valuation
P/E — · PEG —
0% evidence
3.0/20Relative strength
RS sector -28% · RS bench -18.1% · 1Y -14.6%
70% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
McKesson Corporation has the highest Revenue among the 8 Medical Distribution companies compared here, at $403,430 million. Cencora, Inc. is next at $328,681 million. Cardinal Health, Inc. has the highest Revenue growth at 12.8%, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: McKesson Corporation is the scale leader at $403,430 million, 22.7% ahead of Cencora, Inc.. Cardinal Health, Inc.'s growth is 12.8% from a $250,735 million base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderMcKesson Corporation · $403,430 million
Gap22.7% versus #2 · Cencora, Inc.
Persistence8/8 recent comparable periods
Coverage6/8 companies · 132 observations
Investor read: McKesson Corporation is the scale benchmark; Cardinal Health, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: McKesson Corporation's growth falls below Cardinal Health, Inc.'s for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1McKesson Corporation MCK$403.4B
2Cencora, Inc. COR$328.7B
3Cardinal Health, Inc. CAH$250.7B
4Henry Schein, Inc. HSIC$13.4B
5Accendra Health, Inc. ACH$2.7B
Revenue growthfastest growers
1Cardinal Health, Inc. CAH13%
2McKesson Corporation MCK12%
3EDAP TMS S.A. FOCL12%
4Cencora, Inc. COR6.0%
5Henry Schein, Inc. HSIC5.6%
Revenue · company comparison
6/8 level · 6/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Empro Group Inc. has the highest OPM among the 8 Medical Distribution companies compared here, at 36.1%. Henry Schein, Inc. is next at 5.4%. The same company also holds the highest Margin change, at +65.6 percentage points. 7 of 8 companies report a comparable reading, the latest through Dec 2024.
What the numbers say: Empro Group Inc. leads both opm at 36.1% and margin change at +65.6 percentage points.
LeaderEmpro Group Inc. · 36.1%
Gap568.5% versus #2 · Henry Schein, Inc.
Persistence1/2 recent comparable periods
Coverage7/8 companies · 123 observations
Investor read: Empro Group Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Empro Group Inc. EMPG · older report36%
2Henry Schein, Inc. HSIC5.4%
3Accendra Health, Inc. ACH2.7%
4McKesson Corporation MCK2.2%
5Cencora, Inc. COR1.5%
Margin changefastest expanders
1Empro Group Inc. EMPG · older report+65.6 pp
2EDAP TMS S.A. FOCL+2.8 pp
3McKesson Corporation MCK+0.4 pp
4Cencora, Inc. COR+0.1 pp
5Henry Schein, Inc. HSIC−0.1 pp
Operating margin · company comparison
7/8 level · 7/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
McKesson Corporation has the highest Net profit among the 8 Medical Distribution companies compared here, at $5,099 million. Cencora, Inc. is next at $2,553 million. Cencora, Inc. has the highest Profit growth at 49.6%, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: McKesson Corporation leads with $5,099 million of TTM profit, 99.7% above Cencora, Inc.. Cencora, Inc. shows 49.6% growth from a $2,553 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderMcKesson Corporation · $5,099 million
Gap99.7% versus #2 · Cencora, Inc.
Persistence5/8 recent comparable periods
Coverage6/8 companies · 132 observations
Investor read: McKesson Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1McKesson Corporation MCK$5.1B
2Cencora, Inc. COR$2.6B
3Cardinal Health, Inc. CAH$1.5B
4Henry Schein, Inc. HSIC$418M
5EDAP TMS S.A. FOCL$-32M
Profit growthfastest growers
1Cencora, Inc. COR50%
2McKesson Corporation MCK47%
3Henry Schein, Inc. HSIC1.0%
4Cardinal Health, Inc. CAH-0.7%
Net profit · company comparison
6/8 level · 4/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Cencora, Inc. has the highest CAPEX among the 8 Medical Distribution companies compared here, at $166 million. Cardinal Health, Inc. is next at $146 million. Akso Health Group has the highest CAPEX intensity at 2514.3%, so level and change sit with different companies. 8 of 8 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Cencora, Inc. reports $166 million of CAPEX; Akso Health Group has the highest covered intensity at 2514.3%. Coverage is only 8 of 8 companies and 110 reported observations, so this is partial evidence—not a complete sector rank.
LeaderCencora, Inc. · $166 million
Gap13.7% versus #2 · Cardinal Health, Inc.
Persistence8/8 recent comparable periods
Coverage8/8 companies · 110 observations
Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.
This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
CAPEXlargest spenders
1Cencora, Inc. COR$166M
2Cardinal Health, Inc. CAH$146M
3McKesson Corporation MCK$111M
4Accendra Health, Inc. ACH$42M
5Henry Schein, Inc. HSIC$25M
CAPEX intensityhighest reinvestment intensity
1Akso Health Group AHG2,514%
2Accendra Health, Inc. ACH6.7%
3Henry Schein, Inc. HSIC0.7%
4Cardinal Health, Inc. CAH0.2%
5Cencora, Inc. COR0.2%
Capital expenditure · company comparison
8/8 level · 8/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.
Full annual capacity base, operating cash flow, CAPEX and free cash flow history
Capacity base · net fixed assets + CWIP · fiscal-year history
Empro Group Inc. has the lowest Gross debt among the 8 Medical Distribution companies compared here, at $2 million. EDAP TMS S.A. is next at $28 million. The same company also holds the lowest Net debt, at $2 million. 7 of 8 companies report a comparable reading, the latest through Dec 2024.
What the numbers say: Empro Group Inc. has the clearest covered balance-sheet capacity with $2 million and gross debt of $2 million. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderEmpro Group Inc. · $2 million
Gap92.9% versus #2 · EDAP TMS S.A.
Persistence0/3 recent comparable periods
Coverage7/8 companies · 122 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1Empro Group Inc. EMPG · older report$2M
2EDAP TMS S.A. FOCL$28M
3Accendra Health, Inc. ACH$2.2B
4Henry Schein, Inc. HSIC$3.7B
5McKesson Corporation MCK$8.6B
Net debtlowest net debt
1Empro Group Inc. EMPG · older report$2M
2EDAP TMS S.A. FOCL$13M
3Accendra Health, Inc. ACH$1.8B
4Henry Schein, Inc. HSIC$3.6B
5McKesson Corporation MCK$4.6B
Debt and balance-sheet capacity · company comparison
7/8 level · 7/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Empro Group Inc. has the highest ROCE among the 8 Medical Distribution companies compared here, at 39.6%. McKesson Corporation is next at 14.9%. The same company also holds the highest ROCE change, at +53 percentage points. 8 of 8 companies report a comparable reading, the latest through Dec 2024.
What the numbers say: Empro Group Inc. leads ROCE at 39.6%, 24.7 percentage points above McKesson Corporation. Empro Group Inc. has the strongest latest improvement at +53 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderEmpro Group Inc. · 39.6%
Gap165.8% versus #2 · McKesson Corporation
Persistence1/1 recent comparable periods
Coverage8/8 companies · 136 observations
Investor read: Empro Group Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Empro Group Inc. EMPG · older report40%
2McKesson Corporation MCK15%
3Cencora, Inc. COR5.3%
4Cardinal Health, Inc. CAH3.6%
5Henry Schein, Inc. HSIC2.3%
ROCE changefastest improvers
1Empro Group Inc. EMPG · older report+53.0 pp
2McKesson Corporation MCK+3.8 pp
3Akso Health Group AHG+0.3 pp
4Accendra Health, Inc. ACH+0.2 pp
5Henry Schein, Inc. HSIC0.0 pp
Return on capital · company comparison
8/8 level · 8/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
McKesson Corporation has the lowest Guarded PEG among the 8 Medical Distribution companies compared here, at 0.46×. Cencora, Inc. is next at 0.47×. Henry Schein, Inc. has the lowest P/E at 21.8×, so level and change sit with different companies. 4 of 8 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: McKesson Corporation has the lowest comparable Guarded PEG at 0.46×, 2.1% below Cencora, Inc.. Only 4 of 8 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderMcKesson Corporation · 0.46×
Gap2.1% versus #2 · Cencora, Inc.
Persistence0/8 recent comparable periods
Coverage4/8 companies · 17 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1McKesson Corporation MCK0.5
2Cencora, Inc. COR0.5
3Cardinal Health, Inc. CAH1.0
4Henry Schein, Inc. HSIC3.2
P/Elowest P/E
1Henry Schein, Inc. HSIC21.8
2McKesson Corporation MCK22.5
3Cencora, Inc. COR24.1
4Cardinal Health, Inc. CAH32.3
5Accendra Health, Inc. ACH67.3
Valuation · company comparison
4/8 level · 6/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Accendra Health, Inc. has the lowest EV/EBITDA among the 8 Medical Distribution companies compared here, at 11.5×. Henry Schein, Inc. is next at 13.7×. Henry Schein, Inc. has the lowest P/BV at 2.53×, so level and change sit with different companies. 7 of 8 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Accendra Health, Inc. leads ev/ebitda at 11.5×; Henry Schein, Inc. leads p/bv at 2.53×.
LeaderAccendra Health, Inc. · 11.5×
Gap16.1% versus #2 · Henry Schein, Inc.
Persistence4/8 recent comparable periods
Coverage7/8 companies · 96 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Accendra Health, Inc. ACH11.5
2Henry Schein, Inc. HSIC13.7
3McKesson Corporation MCK15.8
4Cardinal Health, Inc. CAH16.9
5Cencora, Inc. COR18.6
P/BVlowest P/BV
1Henry Schein, Inc. HSIC2.5
2Akso Health Group AHG10.8
3EDAP TMS S.A. FOCL13.8
4Cencora, Inc. COR18.0
Enterprise and book valuation · company comparison
7/8 level · 4/8 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
Empro Group Inc. has the strongest one-year price move in Medical Distribution at +426.1%. EDAP TMS S.A. leads on Mansfield relative strength against the S&P 500 at +63.4%. 4 of 7 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-07-28.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Medical Distribution comparison names 5 specific ways its own evidence can mislead, all listed below. 1 of the 8 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. A high growth rate can still be a low-base artefact.
Keep these limits visible
A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
10 · the complete set
Which companies are included?
All 8 companies in the canonical Medical Distribution membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. 1 of these is no longer being priced, so its price and relative strength are frozen at the last traded week shown.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
This comparison is built from the reported filings of 8 Medical Distribution companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Mar 2026 and market data through 2026-07-28. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Mar 2026 · up to 20 quarters per company
Market dataThrough 2026-07-28 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
These 18 answers restate the Medical Distribution comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-07-28. Nothing here is estimated, and none of it is a recommendation.
Which Medical Distribution company is the biggest?
McKesson Corporation is the largest, with trailing-twelve-month revenue of $403,430 million, ahead of Cencora, Inc. at $328,681 million. That covers 6 of 8 companies with comparable reporting through Mar 2026.
Which Medical Distribution company is growing fastest?
Cardinal Health, Inc. has the fastest revenue growth at 12.8% year on year, across 6 of 8 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Medical Distribution company has the best profit margins?
Empro Group Inc. has the highest operating margin at 36.1%, from 7 of 8 comparable companies. Empro Group Inc. shows the biggest recent improvement, at +65.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Medical Distribution company makes the most profit?
McKesson Corporation earns the most, at $5,099 million of trailing-twelve-month net profit, from 6 of 8 comparable companies. Cencora, Inc. has the fastest profit growth at 49.6%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Medical Distribution company earns the highest return on capital?
Empro Group Inc. leads on return on capital employed at 39.6%, across 8 of 8 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Medical Distribution stock is the cheapest?
On guarded PEG — where a LOWER number is cheaper — McKesson Corporation screens cheapest at 0.46×. Only 4 of 8 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Which Medical Distribution company has the strongest balance sheet?
Empro Group Inc. carries the lowest comparable gross debt at $2 million, from 7 of 8 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Medical Distribution company is investing most in new capacity?
Cencora, Inc. reports the largest capital spending at $166 million, across 8 of 8 companies. Spending consumes cash before it earns anything, so treat the ranking as a diligence queue: check commissioning, utilisation and the return earned on the completed assets before reading spend as value creation.
Is the Medical Distribution sector beating the market?
Medical Distribution has outperformed S&P 500 by 40.3% over the last 52 weeks and 6.4% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 4 of 7 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Medical Distribution stock has the strongest price momentum?
EDAP TMS S.A. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Medical Distribution company scores highest for research priority?
McKesson Corporation scores 71.7 out of 100 with 80.5% evidence confidence, from 28.7 points on growth and earnings, 15.3 on capital efficiency, 15.9 on valuation and 11.8 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Medical Distribution companies does this comparison cover, and over what period?
It compares 8 listed companies over up to 20 reported quarters of fundamentals and 6 fiscal years of capital allocation, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Medical Distribution sector?
The 8 Medical Distribution companies on this page carry $232,410 million of combined market value. McKesson Corporation is the largest at $104,141 million, about 45% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-28.
What is the Medical Distribution sector's P/E ratio?
The median price-to-earnings ratio across the 8 Medical Distribution companies on this page is 32.3×, measured on the 6 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-28.
How is the Medical Distribution sector performing?
4 of the 7 covered Medical Distribution companies are beating S&P 500 on Mansfield relative strength. The sector itself is 40.3% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-07-28.
How many Medical Distribution stocks are listed in the US?
This comparison covers 8 listed Medical Distribution companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Mar 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.